Radu Vasilescu

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

Zoltán Kaló, Zoltán Vokó, Andrew J.K. Östör et al. · Journal of Market Access & Health Policy · 2017 · 42 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacotherapy +17

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment

Peter C. Taylor, Rieke Alten, Juan J. Gómez‐Reino et al. · RMD Open · 2018 · 32 citations · Full text

Medicine, Chronic Disease Control, Chronic Illness Self-management +16

Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access

Karel Pavelká, Nurullah Akkoç, Mustafa Al‐Maini et al. · Rheumatology International · 2017 · 25 citations

Life Sciences, Immunology, Pharmacotherapy +13

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry

Inge Christoffer Olsen, Elisabeth Lie, Radu Vasilescu et al. · Lara D. Veeken · 2018 · 22 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Induction of response with etanercept–methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study

Karel Pavelká, Zoltán Szekanecz, Nemanja Damjanov et al. · Clinical Rheumatology · 2013 · 19 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13